How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):202-4. doi: 10.1007/s00259-013-2593-6.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Digestive System Neoplasms / radiotherapy*
  • Female
  • Humans
  • Male
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Radiopharmaceuticals / therapeutic use*
  • Salvage Therapy*

Substances

  • 177Lu-octreotate
  • Radiopharmaceuticals
  • Octreotide